GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Clinical trials for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot aims to save sight in dry macular degeneration
Disease control Recruiting nowThis study tests an investigational drug called ADX-038 in 240 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. The drug is given as a shot under the skin and is compared to a placebo to see if it can slow the loss …
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 06:10 UTC
-
New injection aims to slow vision loss from dry AMD
Disease control Recruiting nowThis study tests a new treatment called CTx001 for people with geographic atrophy, a form of advanced dry age-related macular degeneration that causes vision loss. The treatment is given as a single injection under the retina. The study will check if it is safe and if it can slow…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: Complement Therapeutics • Aim: Disease control
Last updated May 17, 2026 06:07 UTC
-
New drug trial aims to slow vision loss from dry AMD
Disease control Recruiting nowThis study tests a drug called FWY003 in people with geographic atrophy, a late stage of dry age-related macular degeneration that causes blind spots. About 272 participants will receive either the drug or a placebo to see if it can slow the growth of damaged areas in the eye. Th…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Gene therapy injection aims to slow vision loss from dry AMD
Disease control Recruiting nowThis study tests a new gene therapy (VV-14295) given as an injection into the eye for people with geographic atrophy, a form of advanced dry age-related macular degeneration that causes blind spots. The goal is to see if it is safe and can slow the growth of these spots. About 62…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: Kriya Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Could a tiny zap save your sight? new device trial for dry AMD
Disease control Recruiting nowThis study tests a device that delivers tiny electrical pulses to the eye area for people with intermediate to advanced dry age-related macular degeneration (AMD). About 100 participants will receive either the real treatment or a sham (fake) treatment over 11 months. The goal is…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: NA • Sponsor: i-Lumen Scientific AUS PTY LTD • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New combo therapy aims to slow vision loss from dry AMD
Disease control Recruiting nowThis study tests whether adding a new drug (APL-3007) to an existing treatment (Syfovre) can better slow the progression of geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. About 240 adults aged 60 and older with the condition …
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Electric eye therapy: could a simple device slow blindness?
Disease control Recruiting nowThis study tests if a gentle electrical stimulation applied to the eye (transcorneal electrical stimulation, or TES) is safe and can slow the progression of geographic atrophy, a leading cause of vision loss in older adults. About 70 people aged 60 and older with this condition w…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: NA • Sponsor: Okuvision GmbH • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Eye disease study tracks how vision loss worsens over time
Knowledge-focused Recruiting nowThis study watches how geographic atrophy, a form of advanced age-related macular degeneration, changes over a short period. Researchers will measure vision and eye structure in 75 people aged 55 or older. The goal is to better understand how the disease progresses and what facto…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Sponsor: Complement Therapeutics • Aim: Knowledge-focused
Last updated May 17, 2026 05:53 UTC